Subscribe To
Autolus therapeutics reports third quarter 2023 financial results and business updates
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymp...
November 2, 2023, 11:11 am
Corvus pharmaceuticals to present new interim soquelitinib data from its phase 1/1b t cell lymphoma trial at the 65th american society of hematology (ash) annual meeting & exposition
BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today ...
November 2, 2023, 9:15 am
Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...
November 2, 2023, 2:00 am
Cargo therapeutics begins $100 million ipo rollout
Cargo Therapeutics, Inc. has filed for a $100 million IPO to develop improved CAR T-cell therapy for large B-cell lymphoma. The company's lead candida...
October 23, 2023, 5:47 pm
Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023
– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/...
October 22, 2023, 8:25 am
Syndax: biotech to watch with regulatory filings before end of 2023
Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relap...
October 13, 2023, 2:52 pm
Verastem: signs of life for a beaten-down equity
Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is b...
October 4, 2023, 9:00 pm
Regeneron's (regn) application for blood cancer drug accepted
Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory f...
August 18, 2023, 2:05 pm
Pfizer gets fda accelerated approval for multiple myeloma treatment
A Pfizer Inc. PFE, +0.52% treatment for relapsed or refractory multiple myeloma has received accelerate...
August 14, 2023, 2:40 pm
Caribou biosciences: positive cb-010 data leads to first half 2024 catalyst
Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with ...
July 17, 2023, 5:11 am
Genmab: epkinly's approval not big enough needle-mover (neutral)
Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed<...
June 29, 2023, 10:05 am
Arcellx (aclx) down on hold for lead program cart-ddbcma
Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refract...
June 21, 2023, 11:49 am
Arcellx price target slashed, stock takes a hit as fda puts hold on clinical trial following patient death
Analysts at Baird say they still like the long-term outlook for biotechnology company Arcellx Inc (NASDAQ:ACLX) after a clinical trial for its invest...
June 20, 2023, 4:36 pm
Bristol myers (bmy) announces car t cell therapy breyanzi data
Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in ...
June 19, 2023, 12:29 pm
Roche (rhhby) gets fda approval for blood cancer drug columvi
Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with ...
June 16, 2023, 1:51 pm
Marker therapeutics announces first lymphoma patient treated with mt-601 in phase 1 clinical trial
Marker Therapeutics initiated APOLLO trial for the treatment of lymphoma patients who have relapsed aft...
June 12, 2023, 11:00 am
Kura oncology presents late-breaking clinical data for menin inhibitor ziftomenib at 2023 european hematology association (eha) congress
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (...
June 11, 2023, 7:45 am
Legend (legn) up 4% on snda submission for carvykti expanded use
Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with rela...
June 7, 2023, 9:48 am
Why shares of day one pharmaceuticals are up monday
Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive p...
June 5, 2023, 12:30 pm
Day one biopharmaceuticals shares jump 23% on positive results for glioma treatment
Day One Biopharmaceuticals DAWN, -0.37% shares climbed 23% in premarket trading Monday after the company shared new data on tovorafenib, an investigat...
June 5, 2023, 8:09 am